Interferons multiple sclerosis

Interferon 3-la (Avonex) and interferon 3-lb (Betaseron) are used in the treatment of multiple sclerosis. Interferon y-lb (Actimmune) is used to prevent and diminish the severity of infections associated with chronic granulomatous disease and for delaying the progression of severe, malignant osteopetrosis. 

Relapsing-remitting multiple sclerosis Interferon beta-la-. IM 30 meg Avonex once weekly. Subcutaneous Initially 8.8 meg Rebif 3 times/wk, may increase over 4-6 wk to 44 meg Rebif 3 times/wk. Interferon beta-lb-. Subcutaneous 0.25 mg (8 million... 

Kreisler A, de Seze J, Stojkovic T, Delisse B, Combelles M, Verier A, Hautecoeur P, Vermersch P. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand 2003 107 154-7. 

Feinstein A, O Connor P, Feinstein K. Multiple sclerosis, interferon beta-lb and depression. A prospective investigation. J Neurol 2002 249(7) 815-20. 

The interferon beta-la form (Avonex ) is similarly a immunomodulator used by injection in the treatment of multiple sclerosis. Interferons derived through recombinant DNA technology are labelled (rbe). interferon beta — interferon p. interferon beta-la interferon p. interferon beta-lb interferon p. interferon P2 interleukin 6. interferon yOFN-y MAF immune interferon interferon gamma [ban, inn] formerly called immune interferon Polyferon ) can be isolated from immunologically stimulated T-lymphocytes (hence its former name), and is an IMMUNOMODULAIOR that can be used to treat arthritis and shows activity as an ANTICANCER AGENT. 

Recombinant DNA technology products aldesleukin (IL-2, used in renal cancer) erythropoietin (epoetin alfa, used in anemias) filgrastim (G-CSF, used in neutropenia) interferon alpha (used in hepatitis B and C and in cancer), interferon beta (used in multiple sclerosis) interferon gamma (used in chronic granulomatous disease) oprelvekin (IL-11, used in thrombocytopenia) thrombopoietin (used in thrombocytopenia) and sargramostim (GM-CSF, used in neutropenia). 

Interferon beta-la (AVONEX , Rebif ), interferon beta-lb (Betaferon ), and interferon beta (Fiblaferon ) are applied in multiple sclerosis to reduce both frequency and severity of disease incidents and for the treatment of severe viral infections. In multiple sclerosis, DFN- 3 proteins modulate the destruction of myelin in the cause of the autoimmune reaction. 

Bayas A, Reickmann R Managing the adverse effects of interferon-(3 therapy in multiple sclerosis. Drug Saf 2000 22 149-159. 

Hartung HP, Munschauer F, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 2005 12 588-601. 

Avonex Interferon P-la Biogen Relapsing multiple sclerosis... 

Avonex (Biogen) Interferon-P (IFN-P treatment of multiple sclerosis) 1.2... 

Reder, A. 1996. Interferon Therapy of Multiple Sclerosis. Marcel Dekker. 

Lyseng-Williamson, K. and Plosker, G. 2002. Management of relapsing-remitting multiple sclerosis - defining the role of subcutaneous recombinant interferon-(3-la (Rebif). Disease Management and Health Outcomes 10(5), 307-325. 

Kleinschmidt-DeMasters, B.K., andTyler, K.L., Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1 a for multiple sclerosis, N. Engl. J. Med., 353, 2005. 

BC, Chen L, Hartung HP, Weller M, Wiendl H Interferon-(5 enhances monocyte and dendritic cell expression of B7-H1 (PD-Ll), a strong inhibitor of autologous T-cell activation relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004 155 172-182. 

Interferon beta, which is indicated for multiple sclerosis, is administered parenterally only. The most common side-effects are irritation at the injection site and influenza-like symptoms, such as fever, myalgia, chills and malaise. The side-effects tend to decrease with time. 

A), 3.8 billion Amgen s white blood cell stimulant, Neupogen (filgrastim), 3.0 billion interferon pia (Avonex for multiple sclerosis), 2.2 billion human growth hormone (HGH), 1.8 billion recombinant hepatitis B vaccine ( 1.0 billion) somatropin (Humatrope and Neutropin), 0.9 billion and cerezyme/ceredase (alglucerase), 0.6 billion. 

Interferons (IFN) are glycoproteins that, among other products, are released from virus-infected cells. In neighboring cells, interferon stimulates the production of "antiviral proteins." These inhibit the synthesis of viral proteins by (preferential) destruction of viral DNA or by suppressing its translation. Interferons are not directed against a specific virus, but have a broad spectrum of antiviral action that is, however, species-specific. Thus, interferon for use in humans must be obtained from cells of human origin, such as leukocytes (IFN-a), fibroblasts (IFN-P), or lymphocytes (IFN-y). Interferons are also used to treat certain malignancies and autoimmune disorders (e.g., IFN-a for chronic hepatitis C and hairy cell leukemia IFN-p for severe herpes virus infections and multiple sclerosis). 

Revel M. Interferon-P in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 2003 100 49-62. 

Interferons—Family of immune system signal proteins that interfere with the ability of viruses to infect cells. Interferons have been genetically engineered to provide treatments by weakening immune response in autoimmune disease such as multiple sclerosis, or by strengthening immune response in diseases like hepatitis C. 

Furthermore, not all patients respond positively to a specific drug (e.g. interferon-)S is of clinical benefit to only one in three multiple sclerosis patients see Chapter 4). The range and severity of adverse effects induced by a drug can also vary significantly within a patient population base. 

Fifth, when total refusal is advised, political will is sometimes tested. The best example from the United Kingdom concerns beta interferon for multiple sclerosis NICE twice advised against its use on grounds of lack of cost effectiveness. Faced with a potential political backlash, the ministry devised a risk-sharing plan under which patients were to be monitored over time. If the long-term outcome for patients is not as good as the manufacturers suggest, they may have to refund some of their sales revenues (U.K. Department of Health 2002). 

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownschei-dle CM, Murray TJ et al. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 343(13) 898-904. 

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et al. Effect of early versus delayed interferon beta-lb treatment on disability after a first clinical event suggestive of multiple sclerosis a 3-year follow-up analysis of the BENEFIT smdy. Lancet 2007 370(9585) 389-97. 

AUain H, Schuck S. Observations on difference between interferons used to treat multiple sclerosis. J Chn Res 1998 1 381-92. 

---